Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-03-17 08:00:16
Bergen, Norway, 17 March 2022 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, is pleased to announce that CEO Martin Olin will be
presenting at the Carnegie Virtual Nordic Healthcare Seminar taking place today
at 15:15 CET.
The presentation will be made available on the Company's website in the
Investors section shortly after the presentation.
-Ends-
Contacts
Martin Olin
Chief Executive Officer, BerGenBio ASA
ir@bergenbio.com
Rune Skeie
Chief FinancialOfficer, BerGenBio ASA
rune.skeie@bergenbio.com
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone
ConsiliumStrategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
AboutBerGenBioASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing a
potential companion diagnostic test to identify patient populations most likely
to benefit from AXL inhibition: this is expected to facilitate more efficient
registration trials supporting a precision medicine-based commercialisation
strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit? www.bergenbio.com